Class-B CpG-ODN Formulated With a Nanostructure Induces Type I Interferons-Dependent and CD4+ T Cell-Independent CD8+ T-Cell Response Against Unconjugated Protein Antigen

There is a need for new vaccine adjuvant strategies that offer both vigorous antibody and T-cell mediated protection to combat difficult intracellular pathogens and cancer. To this aim, we formulated class-B synthetic oligodeoxynucleotide containing unmethylated cytosine-guanine motifs (CpG-ODN) with a nanostructure (Coa-ASC16 or coagel) formed by self-assembly of 6-0-ascorbyl palmitate ester. Our previous results demonstrated that mice immunized with ovalbumin (OVA) and CpG-ODN formulated with Coa-ASC16 (OVA/CpG-ODN/Coa-ASC16) elicited strong antibodies (IgG1 and IgG2a) and Th1/Th17 cellular responses without toxic systemic effects. These responses were superior to those induced by a solution of OVA with CpG-ODN or OVA/CpG-ODN formulated with aluminum salts. In this study, we investigated the capacity of this adjuvant strategy (CpG-ODN/Coa-ASC16) to elicit CD8+ T-cell response and some of the underlying cellular and molecular mechanisms involved in adaptive response. We also analyzed whether this adjuvant strategy allows a switch from an immunization scheme of three-doses to one of single-dose. Our results demonstrated that vaccination with OVA/CpG-ODN/Coa-ASC16 elicited an antigen-specific long-lasting humoral response and importantly-high quality CD8+ T-cell immunity with a single-dose immunization. Moreover, Coa-ASC16 promoted co-uptake of OVA and CpG-ODN by dendritic cells. The CD8+ T-cell response induced by OVA/CpG-ODN/Coa-ASC16 was dependent of type I interferons and independent of CD4+ T-cells, and showed polyfunctionality and efficiency against an intracellular pathogen. Furthermore, the cellular and humoral responses elicited by the nanostructured formulation were IL-6-independent. This system provides a simple and inexpensive adjuvant strategy with great potential for future rationally designed vaccines

Visna-Maedi: use of p25-gp44 in a immunoenzymatic test for serological diagnosis.

Visna-Maedi is an infectious dissease, diagnosed fort he first time in Iceland, due to a virus included in the family of Retroviridae. The disease is spreads prevalently among sheep that die after respiratory or nervuos sintomatology. Nowaday there is no effective prophylactics defences against the disease fort he extremly genetic bariability of virus. To achieve a thorough knowledge of epidemiologic situation in the Central Italy, it was carried out a sierologics survey on 131 flocks, 61 from Marche Region and 70 in Umb a, for a total of 1703 sera, It was utilized a immunoenzimathic test (ELISA) using as antigen a ricombinant protein gp25-gp44, obtained through biomolecolar procedures. Among 1703 sera, 970 were serologically positive for MVV. About the flocks 120 showed antibodies against MVV with a positivity percentage of 92. The positive flocks were respectively 64, with 92% in the district of Perugia and 56, with the 91 per cent in the area of Macerata